4SC AG — Capital/Financing Update 2009

Oct 23, 2009

News Details

Ad-hoc | 23 October 2009 11:27

4SC AG Announces Capital Increase

4SC AG / Capital Increase

23.10.2009

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Ad hoc announcement in accordance with §15 WpHG (Securities Trading Act)
Increase in share capital

4SC Announces Capital Increase

Planegg-Martinsried, Germany, October 23, 2009 - 4SC AG (Frankfurt, Prime
Standard: VSC) the drug discovery and development company, today announced
that its Management Board, with the approval of the Supervisory Board,
decided to increase the Company's share capital from EUR 28,502,739.00 up
to EUR 39,903,834.00 through the issue of up to 11,401,095 common ordinary
bearer shares at zero par value from the authorised capital. The new shares
will be offered at a subscription price of EUR 3.00 per new share to the
shareholders.

The Company intends to raise in the range of EUR 25 to 30 million. The
proceeds will secure the further development of 4SC's current product
pipeline. In particular, the focus will be on the further development of
clinical and preclinical compounds against auto-immune and cancer
indications, for which proof-of-concept is expected to be achieved within
the next 24 months.

The subscription rights of the shareholders have been protected. The new
shares with dividend rights from 1 January, 2009, can be obtained by
shareholders in a ratio of 5:2 from 27 October until 10 November 2009. In
the following any unsubscribed shares will be offered to new institutional
investors. A public offer for the purchase of the new share capital will
not occur. The approval of the new shares for trading at the Frankfurt
Stock Exchange is not expected before November/December 2009. Further
details of the capital increase will be published in the electronic Federal
Register (Bundesanzeiger), which is expected on the 27 October, 2009.

              - End of ad hoc announcement -

Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

---

Information and Explaination of the Issuer to this News:

Notes to Editor

About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. The company currently has
three clinical programs, with three further clinical trials planned to
commence in 2009. 4SC-101, a small molecule, is in a Phase IIa trial in
Crohn's disease and is due to commence a Phase IIb trial in rheumatoid
arthritis in 2009. 4SC-20, a histone deacetylase inhibitor (HDAC), is in a
Phase II trial in hepatocellular carcinoma (HCC) and is due to commence a
further Phase II trial in Hodgkin's lymphoma in 2009. Drug candidates are
developed until proof-of-concept and subsequently partnered with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties.

4SC was founded in 1997, has 92 employees, and is listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.

For more information please visit www.4sc.com

4SC AG
Yvonne Alexander
Investor Relations & Public Relations
Tel.: +49 (0) 89 70 07 63 66
yvonne.alexander@4sc.com

MC Services (Europe)
Stefan Riedel
Tel.: +49 (0) 89 21 02 28 40
stefan.riedel@mc-services.eu

The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
crubin@troutgroup.com

23.10.2009 Financial News transmitted by DGAP

---

Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---